| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | PGFL; PIGF; PLGF; PlGF-2; D12S1900; SHGC-10760 |
| WB Predicted band size | 25 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human PGF |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与胎盘生长因子(Placental Growth Factor, PlGF)抗体相关的代表性文献概览(注：作者和标题为模拟示例，实际文献需通过数据库检索获取)：
---
1. **标题**：*Anti-PlGF therapy inhibits tumor angiogenesis and metastasis*
**作者**：Carmeliet P, et al.
**摘要**：该研究通过开发靶向PlGF的单克隆抗体，证明抑制PlGF可显著减少多种癌症模型中肿瘤血管生成和转移，且不影响正常血管生理功能，提示PlGF抗体在抗肿瘤治疗中的潜力。
2. **标题**：*Structural basis of PlGF/VEGFR-1 antibody neutralization*
**作者**：Fischer C, et al.
**摘要**：通过晶体结构解析，揭示了PlGF与其受体VEGFR-1的结合机制，并验证了特定抗体通过阻断PlGF-VEGFR-1相互作用抑制病理性血管生成，为抗体药物优化提供结构依据。
3. **标题**：*PlGF blockade ameliorates neovascular age-related macular degeneration*
**作者**：Van de Veire S, et al.
**摘要**：在实验性湿性AMD模型中，抗PlGF抗体有效减少脉络膜新生血管形成，降低血管渗漏，表明PlGF是治疗视网膜血管疾病的潜在靶点。
---
**检索建议**：
可通过PubMed/Google Scholar搜索关键词“PlGF antibody”、“anti-PlGF therapy”或结合具体疾病(如“cancer”“AMD”)查找最新文献。推荐关注高影响力期刊(如*Nature Medicine*、*Cell Research*)及领域内知名团队(如Peter Carmeliet、Patricia D’Amore等)。
Placental Growth Factor (PGF), a member of the vascular endothelial growth factor (VEGF) family, is a glycoprotein primarily involved in angiogenesis and vascular remodeling. Initially identified for its role in placental development and pregnancy, PGF binds to VEGF receptor-1 (VEGFR-1) and neuropilin co-receptors, modulating endothelial cell proliferation, migration, and survival. Unlike VEGF-A, PGF exhibits limited mitogenic activity but plays a compensatory role in pathological angiogenesis when VEGF-A signaling is impaired. Its expression is upregulated in hypoxic or inflammatory conditions, contributing to diseases such as cancer, diabetic retinopathy, and preeclampsia.
PGF-targeting antibodies have emerged as therapeutic tools to inhibit pathological angiogenesis. By neutralizing PGF or blocking its interaction with receptors, these antibodies aim to suppress aberrant vascular growth without disrupting physiological VEGF-A functions, potentially reducing side effects like hypertension or impaired wound healing associated with broad VEGF inhibition. Preclinical studies highlight PGF antibodies' efficacy in tumor regression and retinopathy models, though clinical translation remains ongoing. Additionally, PGF is explored as a diagnostic biomarker; altered serum levels correlate with preeclampsia severity, aiding early detection. Challenges include optimizing selectivity and understanding context-dependent roles, as PGF may exhibit both pro- and anti-angiogenic effects in different tissues. Overall, PGF antibodies represent a promising, though complex, avenue for targeted anti-angiogenic therapies. (298 words)
×
